Eli Lilly and Company announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.
INDIANAPOLIS, Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson, group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity.
“Phil has had a meaningful impact on Lilly over the last 28 years,” said Anat Ashkenazi, executive vice president and chief financial officer at Lilly. “Through his deep financial knowledge and understanding of the business, industry and stakeholders, Phil has played a key leadership role in the company and is well recognized for his commitment to Lilly’s purpose and the patients we serve. Additionally, he is known for his passion for talent development, having invested significant time mentoring and coaching colleagues across the globe.”
Throughout his tenure, Johnson supported a variety of operations, including Lilly affiliates in Japan and Spain, global manufacturing and quality organizations, and business development activities. He led Lilly’s investor relations group for 11 years and was consistently named Top Investor Relations Officer by Institutional Investor. He has served as Lilly’s treasurer since 2018 and has led the company’s efforts within the financial community to drive positive social and economic change for underrepresented groups.
Johnson’s successor will be named at a future date.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY
Lilly Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including related to leadership changes and Lilly’s strategy, and reflects Lilly’s current beliefs and expectations. There can be no assurance that the leadership changes will achieve Lilly’s objectives or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly’s business, please see Lilly’s most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
Refer to: Carrie Munk, munk_carrie@lilly.com, 317-416-2393
View original content to download multimedia:https://www.prnewswire.com/news-releases/philip-johnson-to-retire-as-lilly-treasurer-302058585.html
SOURCE Eli Lilly and Company
Company Codes: NYSE:LLY
